Kaken Pharmaceutical Co Ltd (Kaken) develops pharmaceutical products and agrochemicals. The company focuses on the manufacture and sale of pharmaceuticals, medical devices, and agricultural chemicals. It also operates in the real estate sector through rental activities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company primarily engages in the research and development of pharmaceuticals, including fundamental research and clinical trials. Additionally, it is involved in the creation of agricultural chemicals. The company concentrates on R&D fields such as the immune system, nervous system, and infectious diseases, while also exploring new fields and modalities. The company is also leveraging AI, big data, and real-world data to enhance drug discovery and development processes. As for clinical advancement, Ivermectin 0.5% topical (KAR), a head lice treatment obtained through a licensing agreement with Arbor Therapeutics, is presently in the Phase III trial stage. KP-001, a remedy for refractory vascular malformations, is presently in Phase III trials in Japan, and an IND has been submitted in the US, with Phase I trials underway. Phase I trials are currently in progress for KP-483, an internally developed cancer immunotherapy drug; KP-910, an internally developed treatment for peripheral neuropathic pain; NM26-2198, a therapy for atopic dermatitis developed jointly with Pneumab Therapeutics; Seradelper, a treatment for primary biliary cholangitis acquired through a licensing agreement with Cimabay Therapeutics; and Tildacelfont, treatment for congenital adrenal hyperplasia obtained through a licensing agreement with Spruce Biosciences. The company operates two drug research centers in Kyoto and Shizuoka. In FY2025, the company spent JPY18,725 million on its R&D activities, which as a percentage of revenue stood at 19.9% and grew 49.3% YoY.